Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 26.47 percent increase over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $1.17 million which beat the analyst consensus estimate of $1.14 million by 2.82 percent. This is a 49.68 percent increase over sales of $783.00 thousand the same period last year.